Global Cholangiocarcinoma Alliance

Name

Global Cholangiocarcinoma Alliance

Legal name

Global Cholangiocarcinoma Alliance

Website

https://globalccaalliance.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Thames Ditton

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

The Global Cholangiocarcinoma Alliance (GCA) is a nonprofit healthcare communications and advocacy organization that raises awareness, disseminates education, and provides support resources to the global cholangiocarcinoma (bile duct cancer) patient and caregiver community. Its core activity is coordinating advocacy, awareness campaigns, and educational content aimed at improving outcomes for people affected by this rare cancer worldwide.

Product overview

The Global Cholangiocarcinoma Alliance is a healthcare advocacy organization, not a technology product company. Its offerings consist of awareness campaigns (World Cholangiocarcinoma Day, #BeClearOnCCA), a digital pledge program, and educational patient resources. The organization functions as a communications hub connecting patient advocacy groups, healthcare professionals, and researchers globally rather than offering software products or services.

Differentiator

Problem solved

Functional benefit

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered core.

• ATUVIBI (Bile Duct Tumor Association)coreStrategic or Co-development Partner · 1 February 2024Founded in Spain in February 2024, ATUVIBI advocates for patients and caregivers affected by biliary tract cancers, promoting awareness, research, and collaboration to enhance diagnosis, treatment, and quality of life.
• APIC (Associazione Pazienti Italiani di Colangiocarcinoma)coreStrategic or Co-development Partner · 1 January 2019Established in January 2019, APIC addresses any issues related to CCA, whether helping individuals or acting at the public level.
• Cholangiocarcinoma Research Institute (CARI), Khon Kaen UniversitycoreStrategic or Co-development Partner · 1 January 2018Coordinates national and international collaboration to advance research, knowledge, and technology for preventing, diagnosing, and treating liver fluke infection and cholangiocarcinoma, while strengthening standards, community practices, and researcher development.
• Department of Surgery, Faculty of Medicine, Khon Kaen UniversitycoreStrategic or Co-development Partner · 1 January 2018Thailand's leading centre for cholangiocarcinoma prevention, screening, research, and advanced hepatobiliary surgery, working alongside CARI.
• Cholangiocarcinoma Foundation AustraliacoreStrategic or Co-development PartnerA patient-led foundation re-engineering how cholangiocarcinoma is prevented, detected, and responded to. Simplifies complexity, empowers patients, accelerates science, and builds survival systems.
• Jarurat Care FoundationcoreStrategic or Co-development PartnerPatient advocacy for GI Cancers in India that helps individuals facing serious illnesses access essential care, information, and assistance. Provides guidance, improves treatment access, and supports people through complex healthcare journeys.
• AMMF - The Cholangiocarcinoma CharitycoreStrategic or Co-development PartnerThe UK's only cholangiocarcinoma charity. Working to raise awareness, provide information to those who need it, and to encourage and support research. AMMF established the inaugural World Cholangiocarcinoma Day in 2016.
• Cholangiocarcinoma FoundationcoreStrategic or Co-development PartnerUS-based foundation with the mission to support patients and render cholangiocarcinoma a treatable disease.
• Canadian Cholangiocarcinoma Collaborative (C3)coreStrategic or Co-development PartnerA partnership among patients, caregivers, oncologists and researchers formed to grow hope in patients and families affected by biliary tract cancers.
• AXON CommunicationscoreOthersA global healthcare communications agency that ignites change in healthcare. Believes in partnering with communities to drive meaningful change in health. Collaboration and co-creation are at the heart of how they bring communities together - working with the community, for the community.

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• APIC (Associazione Pazienti Italiani di Colangiocarcinoma): Italian CCA patient association established in January 2019, addressing CCA issues at individual and public levels. GCA steering-committee member and a directly comparable national CCA advocacy peer.
• Canadian Cholangiocarcinoma Collaborative (C3): C3 is a partnership of patients, caregivers, oncologists, and researchers in Canada serving those affected by biliary tract cancers. It is a direct CCA peer and GCA steering-committee member, with the same multi-stakeholder coalition model.
• AMMF - The Cholangiocarcinoma Charity: AMMF is the UK's only CCA charity and the originator of World CCA Day (2016). It is a founding GCA member, with GCA's CEO Helen Morement simultaneously serving as AMMF CEO. The two organizations are functionally sister entities in the global CCA ecosystem.
• Cholangiocarcinoma Foundation: US-based CCA foundation with a mission to render CCA a treatable disease. It is a core GCA partner and shares the GCA's awareness and patient-support mission, making it the closest US comparable and a fellow steering-committee member.
• ATUVIBI (Bile Duct Tumor Association): Spain-based association founded February 2024 advocating for biliary tract cancer patients and caregivers. Direct CCA peer operating in a national market under the same coalition umbrella as the GCA.
• Cholangiocarcinoma Foundation Australia: Australian patient-led CCA foundation that re-engineers CCA prevention, detection, and response. It is a GCA steering-committee member and operates the same awareness + research advocacy model in the APAC region.
• Jarurat Care Foundation: India-based patient advocacy foundation for GI cancers, helping patients navigate diagnosis and access care. Direct regional peer with overlapping CCA patient-support mission and a GCA steering-committee seat.

Broad incumbents

• World Pancreatic Cancer Coalition: Global coalition of pancreatic cancer advocacy organizations. While focused on pancreatic rather than biliary cancer, it operates the same multi-national-charity coalition model with annual awareness days (World Pancreatic Cancer Day) and shared awareness assets — a direct structural analog to the GCA.
• AXON Communications: Global healthcare communications agency and the publishing parent of the GCA (company registration 608275). AXON provides communications infrastructure, content, and digital operations for the alliance and serves many similar disease-awareness initiatives across healthcare.

Emerging players

• Target Ovarian Cancer: UK-based charity driving awareness and earlier diagnosis of ovarian cancer — a similarly low-survival, low-awareness cancer where awareness campaigns and HCP education have measurable impact. Comparable model for rare-gynecological-cancer awareness advocacy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CCA_Alliance
• Facebookfacebook.com/globalCCAalliance
• LinkedInlinkedin.com/company/globalccaalliance
• Instagraminstagram.com/cca_alliance

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Cholangiocarcinoma Alliance